ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2230

Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis

Maria Garcia-Gonzalez1, Fuensanta Gomez-Bernal2, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, Comorbidity, complement, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which has been attributed to the inflammation present in the disease. In this study, we aimed to evaluate the association between a comprehensive assessment of the complement system and the lipid profile of RA patients.

Methods: Four hundred thirty patients were recruited. New-generation techniques were employed to conduct functional assays of the three pathways of the complement system. Serum levels of various complement components such as C1q, lectin, C2, C4, C4b, C1-inhibitor, C3a, C5, C5a, and C9 were assessed. Furthermore, a complete pattern of lipid molecules was measured including high (HDL), low-density lipoproteins (LDL), and lipoprotein(a). Multivariable linear regression analysis was conducted to investigate the association between the complement system and lipid profile in RA patients.

Results: Demographic- and disease-related characteristics of the participants are shown in supplementary table 1.

Spearman’s rho correlation heatmap analysis of C system pathways and individual particles to lipid profile molecules are shown in figure 1-A. Most of the associations were positive (in red). Only HDL and ApoA1, which are molecules with beneficial lipid properties, showed a negative relationship (in green). Significant associations were predominant in the upper part of the heatmap, corresponding to the upstream C zymogens. Thus, C1q, which belongs to the early classical pathway, showed a significant relationship with all C molecules except HDL, apolipoprotein A1, and lipoprotein(a). Properdin also showed associations with all lipid profile molecules apart from apolipoprotein A1 and lipoprotein(a). C1-inhibitor, factor I, and C3a were among the particles that showed higher associations with different lipid molecules. The C activation products C3a and C5a did not show association with the lipid profile.

Standardized beta coefficients in figure 1-B are adjusted for age, sex, abdominal circumference, use of statins, anti-TNF therapies and tocilizumab, and DAS28-CRP. C1q retained significant and positive associations with non-HDL and LDL-cholesterol, LDL:HDL and ApoB:ApoA1 ratios, ApoB, and the atherogenic index. Also, properdin serum levels were significantly associated with total cholesterol, non-HDL, LDL and LDL:HDL ratio and atherogenic index. Several other associations identified in the univariable analysis were also preserved. Again, functional C assays and activated C forms showed no correlation with the lipid pattern.

To ascertain how our findings correlate with specific lipid values known to impact cardiovascular disease or cardiovascular events, we examined the association of the C system with LDL >130 mg/dl, an atherogenic index >4, and the presence of dyslipidemia. This analysis was adjusted for the aforementioned potential confounders. Its results are shown in table 1.

Conclusion: Patients with RA exhibit an independent relationship between the C system and a detrimental lipid profile. This relationship is primarily associated with upstream complement components rather than activated ones.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Garcia-Gonzalez: None; F. Gomez-Bernal: None; J. Quevedo-Abeledo: None; M. Gonzalez-Gay: None; i. Ferraz-Amaro: AbbVie/Abbott, 5, 6, Celgene, 6, Janssen, 5, Merck/MSD, 5, 6, Pfizer, 6, Roche, 5, 6, sanofi, 6.

To cite this abstract in AMA style:

Garcia-Gonzalez M, Gomez-Bernal F, Quevedo-Abeledo J, Gonzalez-Gay M, Ferraz-Amaro i. Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/relationship-between-the-complement-system-and-serum-lipid-profile-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-the-complement-system-and-serum-lipid-profile-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology